Navigation Links
Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/3/2011

SAN DIEGO, Nov. 3, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the Company's financial results for the quarter ended September 30, 2011.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Optimer reported total revenues for the third quarter of 2011 of $11.1 million, compared $669,000 for the third quarter in 2010. This includes net product sales of $10.6 million recognized from the sale of DIFICID™. Optimer recognizes product sales of DIFICID upon delivery of product to its wholesalers.

  • For the quarter ended September 30, 2011, the $10.6 million in net sales to wholesalers reflected a total of 4,335 DIFICID treatments
  • 2,505 DIFICID treatments were shipped from wholesalers to hospitals, retail pharmacies and long-term care facilities in the quarter ended September 30, 2011
  • 535 hospitals had ordered DIFICID as of September 30, 2011
  • 304 hospitals had placed DIFICID on formulary, and 346 hospital formulary reviews were pending as of October 21, 2011.

  • "In only a few months since our first DIFICID sale on July 19th we've seen significant interest in DIFICID converting into uptake and adoption. We reported $10.6 million in sales to our wholesalers in the third quarter, and we expect continued strong uptake as the launch progresses," said Pedro Lichtinger, President and CEO of Optimer. "This confirms our belief that DIFICID meets the need for a Clostridium difficile-associated diarrhea treatment addressing the problem of recurrence by providing a sustained clinical response. As the medical community becomes more familiar with and recognizes the value of DIFICID, we anticipate that adoption will continue."Optimer reported a net loss for the third quarter of 2011 of $26.4 million, or ($0.57) 
    '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
    2. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
    3. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
    4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
    5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
    6. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
    7. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
    8. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
    9. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
    10. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
    11. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/14/2014)... In recent years, growing suspicion about the ... development and promotion has led to unprecedented levels of ... concerns about the insidious impact of commercialization of research, ... to the world’s biggest pharmas for illegal marketing activities, ...
    (Date:1/14/2014)... OTTAWA, Ontario , Jan. 14, 2014   Kinaxis ®, ... ( SCM ) and sales and operations planning ( S&OP ... the Biomanufacturing Summit , which will be held at ...  At the conference, join Kinaxis customer Elisabeth Kaszas , ...
    (Date:1/14/2014)... 2014 During the 1600’s through the 1800’s ... Doctor’s Plague.” In this time period, doctors did not know ... times, to the death of vulnerable patients. In the same ... they may be unwittingly transmitting herpes viruses to their patients. ...
    (Date:1/14/2014)... Holloway America today announced an addition to ... (MTRs) for all pressure vessels and tank parts the ... important for equipment that must meet ASME, CE, PED, ... functionality that allows authorized users to quickly locate and ...
    Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 3
    ... Symbol: MS , , , ... Medical Corp. (TSX: MS), today announced that the University of Alberta , a major shareholder ... , , Certain employees, officers ... Alberta . , , , ...
    ... Smartfield, ... was approved for $250,000 for completion and commercialization of their SmartCrop® technology. SmartCrop is ... , ... 30, 2010 -- Smartfield, Inc. is an information company that develops and ...
    ... ATLANTA , April 29 Xoft, Inc., developer of ... therapy directly to cancer sites with minimal radiation exposure to surrounding ... for the treatment of skin cancer. The announcement was made here ... April 29-May 1 . , ...
    Cached Biology Technology:BioMS Medical updates University of Alberta equity position 2$250,000 Awarded to Smartfield, Inc. of Lubbock, TX by the Texas Emerging Technology Fund 2Xoft's Electronic Brachytherapy Hits Milestone With 10 New Skin Cancer Installations 2Xoft's Electronic Brachytherapy Hits Milestone With 10 New Skin Cancer Installations 3Xoft's Electronic Brachytherapy Hits Milestone With 10 New Skin Cancer Installations 4
    (Date:4/22/2014)... 2014 Scientists from the Florida campus of The ... that plays a critical but previously unknown role in ... showed a novel role for a protein known as ... eLife , a publisher supported by the Howard ... Wellcome Trust. , "This is a critical building block ...
    (Date:4/22/2014)... nanotechnology expert will present a poster titled ... 7th International Nanotoxicology Congress to be held ... Monita Sharma will outline a strategy consistent with the ... " Toxicity Testing in the 21st Century: A Vision ... methods involving human cells and cell lines for mechanistic ...
    (Date:4/22/2014)... Experimental Biology (FASEB) has released updated factsheets ... the National Institutes of Health (NIH) benefits each of ... pleased to make these factsheets available to help citizens ... state," said FASEB President, Margaret K. Offermann, MD, PhD. ... research funding, investing $29.2 billion in FY 2013 in ...
    Breaking Biology News(10 mins):Scientists identify critical new protein complex involved in learning and memory 2
    ... This press release is available in French ... and men contribute equally to the lineage of contemporary populations? ... polygamy or monogamy? To answer these questions, Dr. Damian Labuda, ... a professor at the Department of Pediatrics of the Universit ...
    ... professor of chemistry at New Jersey Institute of ... patent today for a novel composition of matter. ... (US Patent Number 7,670,684) discloses a new self-contained ... comprised of organic scaffolds with metal centers, which ...
    ... worldwide. It is the most common form of age-related dementia, ... no cure, and the available drugs only help to relieve ... characteristic changes in the brains of Alzheimer,s patients is the ... curing or at least slowing the disease lies in developing ...
    Cached Biology News:Modern man found to be generally monogamous, moderately polygamous 2NJIT researcher awarded patent for hydrophobic, corrosion-resistant coating 2The sea squirt offers hope for Alzheimer's sufferers 2
    Candida (IgG) -Ab EIA Sample Size: 5 l...
    Candida (IgA) -Ab EIA Sample Size: 5 l...
    Automated centrifuge for the processing of microplates and tubes; can be integrated into automated process using inexpensive robotics due to its unique sample handling platform....
    ... the first higher plant to be fully ... primary model organism for gene expression research ... microarray is derived from the ATH1 v.5 ... (TIGR) and from the Arabidopsis MPSS database ...
    Biology Products: